Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences

Annals of Internal Medicine

Volumn 134, Issue 3, 2001, Pages 224-238

  Rauch, U ^a   Osende, J I ^a   Fuster, V ^a   Badimon, J J ^a   Fayad, Z ^a   Chesebro, J H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTISTASIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; COUMARIN ANTICOAGULANT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; THIENO[2,3 B]PYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICK ANTICOAGULANT PEPTIDE; TICLOPIDINE; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN;

ARTERY THROMBOSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD RHEOLOGY; DATA BASE; DRUG EFFECT; DRUG EFFICACY; EROSION; HEART MUSCLE ISCHEMIA; HUMAN; LONG TERM CARE; MEDICAL INFORMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOGENESIS; THROMBOGENICITY; TREATMENT OUTCOME;

EID: 0035814837     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-3-200102060-00014     Document Type: Review

References (173)

1. Future cardiovascular endpoint studies: Where will the research take us?
2. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
3. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
4. Pathogenesis of thrombosis in coronary artery disease
5. A macro and micro view of coronary vascular insult in ischemic heart disease
6. Vulnerable plaque: Pathobiology and clinical implications
7. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association
8. Acute coronary syndromes: Biology
9. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions
10. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: The biologic role of risk factors
11. Pathophysiology and clinical significance of atherosclerotic plaque rupture
12. The contribution of thrombosis to the clinical expression of coronary atherosclerosis
13. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
14. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults
15. USA Multicenter Study of the pathobiology of atherosclerosis in youth
16. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association
17. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture
18. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
19. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity
20. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
21. Tissue factor and hemostasis
22. Tissue factor: Then and now
23. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
24. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi
25. The atheromatous lipid core
26. Relation of plaque lipid composition and morphology to the stability of human aortic plaques
27. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture
28. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
29. The matrix degrading metalloproteinases
30. Molecular bases of the acute coronary syndromes
31. Mechanical factors affecting hemostasis and thrombosis
32. Flow-mediated endothelial mechanotransduction
33. Laminar shear stress: Mechanisms by which endothelial cells transduce an atheroprotective force
34. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow
35. Mechanisms of arterial thrombosis in nonparallel streamlines. Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model
36. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study
37. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death
38. Lipoprotein(a). A unique risk factor for atherothrombotic disease
39. Platelet lipoprotein interactions
40. Statins and cardiovascular disease: The multiple effects of lipid-lowering therapy by statins
41. Cholesterol reduction yields clinical benefit: Impact of statin trials
42. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
43. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
44. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
45. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
46. Prevention of cardiovascular events and a death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
47. Effect of lipid lowering by pravastatin on progression and regression of coronary disease in symptomatic men with normal to moderately elevated cholesterol levels
48. Hemostasis and cardiovascular risk. The British and European experience
49. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies
50. Activation markers of coagulation and fibrinolysis: Alterations and predictive values in acute coronary syndromes
51. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
52. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group
53. Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men
54. Production of C-reactive protein and risk of coronary events in stable and unstable angina
55. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
56. Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience
57. Effect of intensive diabetes management on macrovascular event and risk factors in the Diabetes Control and Complications Trial
58. Mechanism determining course and outcome of diabetic patients who have had acute myocardial infarction
59. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study
60. Coagulation activation in diabetes mellitus: The role of hyperglycaemia and therapeutic prospects
61. Mechanism on disorders of coagulation and fibrinolysis in diabetes
62. Platelet activation in diabetic cardiovascular autonomic neuropathy
63. Platelet-leukocyte-cross-talk in diabetes mellitus
64. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2
65. Platelet activation in diabetic microangiopathy
66. Microalbuminuria in IDDM is associated with increased expression of monocyte procoagulant activity
67. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men
68. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina
69. Disseminated intravascular coagulation: Clinical and laboratory aspects
70. Role of tissue factor in disseminated intravascular coagulation
71. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation
72. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction
73. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease
74. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia
75. Blood-borne tissue factor: Another view of thrombosis
76. Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface
77. Mechanism of action of thrombin on platelets
78. Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate; the importance of perfusion conditions
79. Lower extremity arterial disease and the aging process: A review
80. Intermittent claudication. Current results of non-operative management
81. Influence of coronary heart disease on morbidity and mortality after lower extremity revascularizadon surgery: A population-based study in Olmsted County, Minnesota (1970-1987)
82. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population
83. Fate of the patients with chronic leg ischaemia. A review article
84. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content
85. Atherosclerosis of the ascending aorta. Prevalence and role as an independent predictor of cerebrovascular events in cardiac patients
86. Proximal aortic atheroma. An independent risk factor for cerebral ischemia
87. Atheroembolism from the ascending aorta. An emerging problem in cardiac surgery
88. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke
89. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke
90. Noninvasive detection of atherosclerosis
91. Ultrasound B-mode imaging in observational studies of atherosclerotic progression
92. Endothelial dysfunction: Does it matter? Is it reversible?
93. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study
94. Electron-beam computed tomography, coronary artery calcium, and evaluation of patients with coronary artery disease
95. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
96. Values of electron-beam computed tomography for the noninvasive detection of high-grade coronary-artery stenoses and occlusions
97. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study
98. T2-weighted contrast for NMR characterization of human atherosclerosis
99. In-vivo MR characterization of plaques in the thoracic aorta
100. New antithrombotic agents
101. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study
102. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial
103. Aspirin as an antiplatelet drug
104. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial
105. Low-molecular-weight heparins
106. Low-molecular-weight heparin during instability in coronary artery disease
107. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
108. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome
109. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
110. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to assess strategies for ischemic syndromes (OASIS) pilot study results
111. Progression of the culprit lesion in unstable coronary disease with warfarin and aspirin versus aspirin alone: Preliminary study
112. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
113. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
114. The veterans administration cooperative study program trial. Combination, hemotherapy and mortality prevention (CHAMP). Rates of major hemorrhage
115. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
116. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stent
117. Clopidogrel versus ticlopidine after intracoronary stent placement
118. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
119. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting
120. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
121. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative (CLASSICS)
122. Platelet GP IIb/IIIa antagonists: The first anti-integrin receptor therapeutics
123. Platelet GPIIb-IIIa blockers
124. Frontiers in interventional cardiology
125. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
126. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
127. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
128. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy
129. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
130. Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
131. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
132. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa receptor inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network
133. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes
134. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists
135. Monitoring platelet GP IIb/IIIa antagonist therapy
136. Heparin
137. Oral anticoagulant drugs
138. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor
139. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs
140. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat
141. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions
142. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
143. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model
144. Tissue factor pathway inhibitor: Potential therapeutic applications
145. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit
146. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor
147. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis
148. Local delivery of a tissue factor antibody reduces early leukocyte infiltration but fails to limit intimal hyperplasia in experimental vein grafts
149. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
150. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
151. Transfer of tissue factor from leukocytes to platelets is mediated by CD 15 and tissue factor
152. Dithiocarbamates ameliorate the effects of endotoxin in a rabbit model of disseminated intravascular coagulation
153. Role of NFκB in the mortality of sepsis
154. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
155. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation
156. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa
157. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis
158. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
159. Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa
160. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats
161. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis
162. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis
163. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits
164. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates
165. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers
166. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide
167. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein
168. Dithiocarbamates as potent inhibitors of nuclear factor κ B activation in intact cells
169. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model
170. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function
171. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa
172. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries